Why is KARD down?
Down 26% from Nov 11 to Nov 20 while the S&P 500 fell 9%.
- Its Nov 12 results:
−2Volatility
Down 26% from Nov 11 to Nov 20 while the S&P 500 fell 9%.
−2Volatility
KARD's Quality Score fell 2 points on Fri, Nov 20, to -2. Trading went back to normal after a busy day (2 chart checks stopped).
New listing, trading since Jun 18, 2026. 109 trading days so far, so 3 of the 14 chart checks wait for more history.
Follow KARD's trial news. Pro members can get an alert when Kardigan files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Holding it back | Moves 10.7% a day with no profit behind it |
| Latest filing | 8-K, Nov 12 |
After its last 2 reports it closed -2.6% on average, higher 1 of 2 times.
$591M in cash
No shelf registration or at-the-market program on file in the last three years.
Director Paul L Berns bought 1,250,000 shares on Jun 22. 1 more insider trade this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
KARD is #54 of 89 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| 54 |
Expected to report Tue Mar 23, before the open (in 122 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
A loss of $0.64 a share, from $4.43.
KARD's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 12, 2026 | -1.7% | -9.9% | -21.4% |
| Aug 11, 2026 | +1.4% | +4.7% | -2.5% |
RSI 35.8, MACD below signal. Not scored.
Officers and directors with a Form 4 in the last 12 months.
In ETFs: KARD is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.
Listed on Nasdaq on Jun 18, 2026, and is 28% below its $16 offer price now. Its IPO filing and first days
KARD scores -2 today, which Breakaway calls Poor. It is #54 of 89 in Pharma by Quality Score, with 0 of 14 chart checks firing. Down 26% from Nov 11 to Nov 20 while the S&P 500 fell 9%. Shares: 6.8 times the count a year ago (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
KARD scores -2 today, which Breakaway calls Poor (below zero). That is #54 of 89 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind KARD's -2.
Expected to report Tue Mar 23, before the open, a date Breakaway expects from the company's usual timing; the company has not confirmed it. KARD closed higher after 1 of its last 2 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.